Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) subsidiary Zydus MedTech has partnered with Brazil-based Braile Biomedica to exclusively commercialize its Transcatheter Aortic Valve Implantation (TAVI) system in Europe, India, and select markets.

Under the agreement, Braile will manufacture and supply the TAVI system, while Zydus will handle commercialization and retain rights to manufacture select components, according to a Thursday filing with the Indian exchanges.

The deal marks Zydus MedTech's entry into the interventional cardiology segment, targeting the $6 billion global TAVI market, it added.